PLSE News & Events

Reports Q1 revenue $401k. "This was a defining quarter for Pulse Biosciences. We sharpened our strategic focus on electrophysiology based on landmark clinical outcomes that reinforced the durability and efficiency of AF treatment with the nPulse catheter and commenced enrollment in our U.S. IDE pivotal trial of our nPulse Cardiac Catheter System," said Paul LaViolette, CEO and Co-Chairman of Pulse Biosciences. "Based on high investigator enthusiasm and early pivotal study progress, we are pleased to update our anticipated enrollment completion timing to early-Q4, 2026. The momentum we are building positions us to advance critical clinical and regulatory milestones that will bring the transformative potential of nanosecond PFA technology to patients and physicians globally."

Pulse Biosciences announced late-breaking "positive" clinical data from its nPulse Cardiac Catheter System first-in-human feasibility study at the Heart Rhythm 2026 meeting. Key study findings on the 5 second ablation cohort include: Sustained 100% procedural success of evaluable patients by holter at 6 months; Sustained 96% procedural success of evaluable patients by holter at one year; Sustained 90% Kaplan-Meier estimate of freedom from AF/AFL/AT at one year; Consistently efficient procedural performance, including: Left atrial dwell time: 18.6 +/- 13.0 minutes, Total procedure time: 60.2 +/- 27.7 minutes, Fluoroscopy time: 9.4 +/- 5.9 minutes, Average applications per-patient for PVI: 12.3 +/- 2.6; Safety profile across total cohort: maintained low serious adverse event rate, with 1.7% of subjects experiencing a SAE related to the primary safety endpoint

Pulse Biosciences announced late-breaking positive clinical data from its nPulse Cardiac Catheter System first-in-human feasibility study at the Heart Rhythm 2026 meeting. Key study findings on the 5 second ablation cohort include: Sustained 100% procedural success of evaluable patients by holter at 6 months; Sustained 96% procedural success of evaluable patients by holter at one year; Sustained 90% Kaplan-Meier estimate of freedom from AF/AFL/AT at one year; Consistently efficient procedural performance, including: Left atrial dwell time: 18.6 +/- 13.0 minutes, Total procedure time: 60.2 +/- 27.7 minutes, Fluoroscopy time: 9.4 +/- 5.9 minutes, Average applications per-patient for PVI: 12.3 +/- 2.6; Safety profile across total cohort: maintained low serious adverse event rate, with 1.7% of subjects experiencing a SAE related to the primary safety endpoint